A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors

NCT06685068 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
23
Enrollment
INDUSTRY
Sponsor class

Stopped Genmab has decided to terminate the GEN1286 program due to an unfavorable benefit-risk profile not supporting further development.

Conditions

Interventions

Sponsor

Genmab